Combination therapy with a BRAF inhibitor and a MEK inhibitor (BRAF/MEKi) has been proven to improve ORR, prolong PFS and OS, and reduce the frequency of secondary tumor development compared with a BRAF inhibitor alone.56, 57, 58, 59. Here, BRAF is linked to neoplasm.